Definitive Contract HHSN272201400031C

This is a $600,000.00 firm fixed-price definitive contract awarded by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases to Epitogenesis Inc., a minority-owned, self-certified small disadvantaged business, economically disadvantaged women-owned small business, and woman-owned business. The contract is for the development of a "novel nano-emulsion immuno-suppressive adjuvant for allergy vaccines" to be performed in Vernon Rockville,...

This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...

The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...

This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $4,148,210.00 Firm Fixed Price Definitive Contract to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, for the development of membrane-anchored cytokines as novel vaccine adjuvants for the elderly. This contract, which has a completion date of December 31, 2022, is part of the agency's "DEVELOPMENT OF MEMBRANE ANCHORED...

This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $224,992 firm fixed price definitive contract to Hafion Inc., a self-certified small disadvantaged and woman-owned small business, to conduct research and development on generating synergy between protein and non-protein macromolecular adjuvants. The contract, which was not set aside, was completed in July 2018. Hafion has also received other prime and...

This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and...

This is a Firm Fixed Price definitive contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Adjuvance Technologies Inc. (doing business as Adjuvance) for the purpose of determining the impact of a semisynthetic saponin immunologic adjuvant called Titerquil-1055 on the immunogenicity and stability of influenza vaccines. The contract has a potential value of $223,002.00 and was completed on July 31,...

This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...